ispronicline

a neuronal nicotinic acetylcholine receptor modulator; has antidepressant, neuroprotective, and cognitive effects; structure in first source

Also Known As:

(S)-(E)-N-methyl-5-(3-(5-isopropoxypyridinyl))-4-penten-2-amine; AZD3480; N-methyl-5-(3-(5-isopropoxypyridinyl))-4-penten-2-amine; TC 1734; TC-1734; TC1734

Networked: 8 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - ispronicline: 8

Experts

1.	Dunbar, Geoffrey: 2 articles (02/2014 - 01/2004)
2.	Gatto, Gregory J: 2 articles (10/2012 - 01/2004)
3.	Hosford, David: 1 article (02/2014)
4.	Mazzulla, Emily: 1 article (02/2014)
5.	Newhouse, Paul A: 1 article (02/2014)
6.	Potter, Alexandra S: 1 article (02/2014)
7.	Cauley, Marty C: 1 article (10/2012)
8.	Johnson, Edwin C: 1 article (10/2012)
9.	Levin, Edward D: 1 article (10/2012)
10.	Rezvani, Amir H: 1 article (10/2012)

Related Diseases

1.	Dementia (Dementias) 01/01/2004 - "Phase I clinical trials demonstrated TC-1734's favorable pharmacokinetic and safety profile by acute oral administration at doses ranging from 2 to 320 mg. The bioavailability, pharmacological, pharmacokinetic, and safety profile of TC-1734 provides an example of a safe, potent and efficacious neuronal nicotinic modulator that holds promise for the management of the hallmark symptomatologies observed in dementia." 05/01/2007 - "These early data in healthy subjects provide encouragement to consider development of AZD3480 as a novel agent for the treatment of cognitive decline in the elderly, including age-associated memory impairment and/or dementia of the Alzheimer's type." 01/01/2011 - "Improvements in a number of secondary outcome measures (MMSE, AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and Disability Assessment for Dementia [DAD]) were observed for AZD3480 and for donepezil. " 01/01/2006 - "Targacept (formerly a subsidiary of RJ Reynolds) is developing ispronicline, the lead in a series of nicotinic acetylcholine (nACh) ligands, as a potential oral treatment for cognitive impairment, including a variety of non-Alzheimer's dementias. "
2.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/01/2014 - "SST performance and total ADHD symptoms were significantly improved with 50 mg of AZD3480. " 02/01/2014 - "We hypothesized that AZD3480 treatment would improve SST performance and clinical symptoms (CAARS-INV Total ADHD Symptoms Score). " 02/01/2014 - "AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults." 02/01/2014 - "This was a within-subjects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (also termed TC-1734) at doses of 5 mg and 50 mg and placebo in adults with ADHD. "
3.	Alzheimer Disease (Alzheimer's Disease) 01/01/2011 - "Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study."
4.	Cognitive Dysfunction 10/01/2012 - "Low doses of AZD3480 may provide therapeutic benefit for reversing attentional impairment in patients suffering from cognitive impairment due to glutamatergic dysregulation and likely other attentional disorders." 05/01/2007 - "These early data in healthy subjects provide encouragement to consider development of AZD3480 as a novel agent for the treatment of cognitive decline in the elderly, including age-associated memory impairment and/or dementia of the Alzheimer's type." 01/01/2006 - "Targacept (formerly a subsidiary of RJ Reynolds) is developing ispronicline, the lead in a series of nicotinic acetylcholine (nACh) ligands, as a potential oral treatment for cognitive impairment, including a variety of non-Alzheimer's dementias. "
5.	Schizophrenia (Dementia Praecox) 01/01/2012 - "Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia."

Related Drugs and Biologics

1.	ispronicline
2.	Nicotinic Agonists
3.	Donepezil (Aricept)
4.	Measles-Mumps-Rubella Vaccine (MMR Vaccine)
5.	Succinic Acid (Succinate)
6.	Fenretinide
7.	Paclitaxel (Taxol)
8.	Vaccines
9.	Etidronic Acid (HEDP)
10.	Sarcosine (Methylglycine)

Related Therapies and Procedures

1.	Oral Administration